Leadership Edge

Srinivasan H R

Chairman & CEO
Navitas Life Sciences

Srinivasan H.R., fondly known as Sri, is the Chief Executive Officer of Navitas Life Sciences. He brings rich experience in Life Sciences, Supply Chain Management and General Management. Sri has run efficient global organizations, as well as led multiple successful mergers & acquisitions. His decades of experience have been pivotal in the establishment of Navitas Life Sciences.

Sri started his career as a Civil Servant in the Government of India. Post that, he successfully held several leadership roles including Executive Director of the Shriram Group, Managing Director of Sembcorp Logistics, Singapore, Managing Director of Temasek Capital, Singapore among others. He has served both on the State and Regional Councils of the Confederation of Indian Industry. He has also served as the Past President of TiE (The Indus Entrepreneurs), Chennai Chapter. In 2008, Sri was conferred with the CII Connect – “Entrepreneur of the Year” and the CII Tamil Nadu “Emerging Entrepreneur” award in 2010. He is a member of the YPO (Young Presidents Organisation).

Camilo E. Horvilleur

Board Member,
Managing Director,
H.I.G. Capital

Camilo is a Managing Director in the U.S. LBO fund and is based in H.I.G.'s Miami office, where he focuses on investment sourcing, transaction negotiation, and portfolio company value creation strategies. Since joining H.I.G. Capital’s U.S. LBO group in 2006, he has helped lead private equity investments in a number of industries including life sciences, healthcare services and business services. Camilo has served on the board of directors of several H.I.G. companies including Navitas Life Sciences, Medusind, Health Network One, US Medical Supply, Capstone Logistics, Koozie Group, Safe-Guard Products, PMSI and Align Networks.

Prior to joining H.I.G., Mr. Horvilleur was with Morgan Stanley in New York, where he focused on communications services and emerging markets. Mr. Horvilleur earned his B.B.A. in Finance from Texas A&M University, summa cum laude, and M.B.A. from Harvard Business School.

Scott Zhu

Board Member,
Managing Director,
H.I.G. Capital

Scott is a Principal in H.I.G. Capital’s Miami office. He is responsible for all aspects of the investment process including sourcing, transaction structuring, financing, and execution of post-closing value creation strategies. Since joining H.I.G. in 2009, Scott has helped lead private equity investments in a number of industries including healthcare, TMT, chemicals, and business services. Scott serves on the board of directors for a number of H.I.G.’s investments including BioVectra, Valtris Specialty Chemicals, Health Network One, and Navitas Life Sciences.

Prior to his current role at H.I.G., Scott was also a member of the management team at a H.I.G. portfolio company, PMSI, a pharmacy benefit manager eventually acquired by Optum, an investor at Staple Street Capital, and a member of the Technology, Media and Telecom group at Bank of America Merrill Lynch. Scott received his undergraduate degree from Yale University.

Alex Zisson

Board Member,
Managing Director & Co-Head of Biohealth ,
H.I.G. Capital

Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Arvelle Therapeutics, Clarus Therapeutics, Leiters Pharmacy, Neurana Pharmaceuticals, Taconic Biosciences, BioVectra, Orbus Therapeutics, and On Target Laboratories.

Prior to H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners.

Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).

Alex is the co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, is on the Advisory Board for Brown University’s Medical School and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America.

He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.